Autoantibody signatures: Progress and perspectives for early cancer detection

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 10, 2011, Pages 2013-2024

  Desmetz, C ^a,b,c   Mange, A ^a,b,c   Maudelonde, T ^a,b,c   Solassol, J ^a,b,c  

^a HÔPITAL ARNAUD DE VILLENEUVE   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

Autoantibodies; Cancer; Early diagnosis; Proteomics; Serum biomarker; Signature; Tumour associated antigen

Indexed keywords

AUTOANTIBODY; EPITOPE; TUMOR MARKER;

BLOOD; EARLY DIAGNOSIS; HUMAN; IMMUNOLOGY; LUNG TUMOR; METHODOLOGY; NEOPLASM; PROTEOMICS; REVIEW;

AUTOANTIBODIES; EARLY DETECTION OF CANCER; EARLY DIAGNOSIS; EPITOPES; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053248927     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01355.x     Document Type: Review

References (70)

1. Etienne R, Urban N, Ramsey S, et al The case for early detection. Nat Rev Cancer. 2003; 3: 243-52.
2. Duffy MJ. Serum tumour markers in breast cancer: are they of clinical value? Clin Chem. 2006; 52: 345-51.
3. Anderson KS, LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res. 2005; 4: 1123-33.
4. Baldwin RW. Tumour-specific immunity against spontaneous rat tumours. Int J Cancer. 1966; 1: 257-64.
5. Baldwin RW. An immunological approach to cancer. Lav Ist Anat Istol Patol Univ Studi Perugia. 1968; 28: 65-85.
6. Baldwin RW. Tumour-associated antigens and tumour-host interactions. Proc R Soc Med. 1971; 64: 1039-42.
7. Kobold S, Lutkens T, Cao Y, et al Autoantibodies against tumour-related antigens: incidence and biologic significance. Hum Immunol. 2010; 71: 643-51.
8. Shoshan SH, Admon A. Novel technologies for cancer biomarker discovery: humoral proteomics. Cancer Biomark. 2007; 3: 141-52.
9. Gaudin E, Hao Y, Rosado MM, et al Positive selection of B cells expressing low densities of self-reactive BCRs. J Exp Med. 2004; 199: 843-53.
10. Wardemann H, Yurasov S, Schaefer A, et al Predominant autoantibody production by early human B cell precursors. Science. 2003; 301: 1374-7.
11. Hansen MH, Nielsen H, Ditzel HJ. The tumour-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. Proc Natl Acad Sci U S A. 2001; 98: 12659-64.
12. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol. 2003; 21: 37-8.
13. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res. 2000; 60: 1777-88.
14. Schubert U, Anton LC, Gibbs J, et al Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000; 404: 770-4.
15. Chen YT, Scanlan MJ, Sahin U, et al A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A. 1997; 94: 1914-8.
16. Ulanet DB, Torbenson M, Dang CV, et al Unique conformation of cancer autoantigen B23 in hepatoma: a mechanism for specificity in the autoimmune response. Proc Natl Acad Sci USA. 2003; 100: 12361-6.
17. von Mensdorff-Pouilly S, Petrakou E, Kenemans P, et al Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer. 2000; 86: 702-12.
18. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res. 2010; 70: 1306-13.
19. Sahin U, Türeci O, Pfreundschuh M. Serological identification of human tumour antigens. Curr Opin Immunol. 1997; 9: 709-16.
20. Tan HT, Low J, Lim SG, Chung MC. Serum autoantibodies as biomarkers for early cancer detection. FEBS J. 2009; 276: 6880-904.
21. Balboni I, Chan SM, Kattah M, et al. Multiplexed protein array platforms for analysis of autoimmune diseases. Annu Rev Immunol. 2006; 24: 391-418.
22. Joos TO, Schrenk M, Höpfl P, et al. A microarray enzyme-linked immunosorbent assay for autoimmune diagnostics. Electrophoresis. 2000; 21: 2641-50.
23. Robinson WH, DiGennaro C, Hueber W, et al. Autoantigen microarrays for multiplex characterization of autoantibody responses. Nature Med. 2002; 8: 295-301.
24. Wang X, Yu J, Sreekumar A, Varambally S, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353: 1224-35.
25. Madoz-Gurpide J, Kuick R, Wang H, et al. Integral protein microarrays for the identification of lung cancer antigens in sera that induce a humoral immune response. Mol Cell Proteomics. 2008; 7: 268-81.
26. Qiu J, Madoz-Gurpide J, Misek DE, et al. Development of natural protein microarrays for diagnosing cancer based on an antibody response to tumour antigens. J Proteome Res. 2004; 3: 261-7.
27. Nam MJ, Madoz-Gurpide J, Wang H, et al. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics. 2003; 3: 2108-15.
28. Mattoon D, Michaud G, Merkel J, Schweitzer B. Biomarker discovery using protein microarray technology platforms: antibody-antigen complex profiling. Expert Rev Proteomics. 2005; 2: 879-89.
29. Hudson ME, Pozdnyakova I, Haines K, et al. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A. 2007; 104: 17494-9.
30. Ehrlich JR, Qin S, Liu BC. The 'reverse capture' autoantibody microarray: a native antigen-based platform for autoantibody profiling. Nat Protoc. 2006; 1: 452-60.
31. Tang L, Yang J, Ng SK, et al. Autoantibody profiling to identify biomarkers of key pathogenic pathways in mucinous ovarian cancer. Eur J Cancer. 2010; 46: 170-9.
32. Dufva M, Christensen C. Diagnostic and analytical applications of protein microarrays. Expert rev Proteomics. 2005; 2: 41-8.
33. Megliorino R, Shi F-D, Peng XX, et al. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev. 2005; 29: 241-8.
34. Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumour-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003; 12: 136-43.
35. Leidinger P, Keller A, Ludwig N, et al. Toward an early diagnosis of lung cancer: an autoantibody signature for squamous cell lung carcinoma. Int J Cancer. 2008; 123: 1631-6.
36. Babel I, Barderas R, Diaz-Uriarte R, et al. Identification of tumour-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol Cell Proteomics. 2009; 8: 2382-95.
37. Taylor BS, Pal M, Yu J, et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics. 2008; 7: 600-11.
38. Mischak H, Allmaier G, Apweiler R, et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med. 2010; 46: doi:.
39. Tan EM, Koziol JA. Autoantibodies in prostate cancer. N Engl J Med. 2005; 353: 2815-7.
40. Kida Y. Autoantibodies in prostate cancer. N Engl J Med. 2005; 353: 2815-7.
41. Rocco B, Djavan B, de Cobelli O. Autoantibodies in prostate cancer. N Engl J Med. 2005; 353: 2815-7.
42. Thorat MA, Badwe RA. Autoantibodies in prostate cancer. N Engl J Med. 2005; 353: 2815-7.
43. Pereira-Faca SR, Kuick R, Puravs E, et al. Identification of 14-3-3 theta as an antigen that induces a humoral response in lung cancer. Cancer Res. 2007; 67: 12000-6.
44. Wu L, Chang W, Zhao J, et al. Development of autoantibody signatures as novel diagnostic biomarkers of non-small cell lung cancer. Clin Cancer Res. 2010; 16: 3760-8.
45. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol. 2011; 22: 383-9.
46. Omenn GS, Goodman G, Thornquist M, et al. Chemoprevention of lung cancer: the beta-Carotene and Retinol Efficacy Trial (CARET) in high-risk smokers and asbestos-exposed workers. IARC Sci Publ. 1996: 67-85.
47. Swensen SJ, Jett JR, Hartman TE, et al. Lung cancer screening with CT: Mayo Clinic experience. Radiology. 2003; 226: 756-61.
48. Henschke CI, Yankelevitz DF, Libby DM, et al. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med. 2006; 355: 1763-71.
49. Pastorino U. Lung cancer screening. Br J Cancer. 2010; 102: 1681-6.
50. Bach PB, Jett JR, Pastorino U, et al. Computed tomography screening and lung cancer outcomes. JAMA. 2007; 297: 953-61.
51. Leidinger P, Keller A, Heisel S, et al.Identification of lung cancer with high sensitivity and specificity by blood testing. Respir Res. 2010; 11: doi:.
52. Chapman CJ, Thorpe AJ, Murray A, et al. Immuno-biomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res. 2011; 17: 1474-80.
53. Rom WN, Goldberg JD, Addrizzo-Harris D, et al. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer. 2010; 10: doi:.
54. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol. 2008; 26: 5060-6.
55. Farlow EC, Patel K, Basu S, et al. Development of a multiplexed tumour-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res. 2010; 16: 3452-62.
56. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007; 356: 227-36.
57. Boyd NF, Martin LJ, Rommens JM, et al. Mammographic density: a heritable risk factor for breast cancer. Methods Mol Biol. 2009; 472: 343-60.
58. Ciatto S, Visioli C, Paci E, Zappa M. Breast density as a determinant of interval cancer at mammographic screening. Br J Cancer. 2004; 90: 393-6.
59. Mandelson MT, Oestreicher N, Porter PL, et al. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst. 2000; 92: 1081-7.
60. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365: 1769-78.
61. Esserman LJ, Shieh Y, Park JW, Ozanne EM. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn. 2007; 7: 533-44.
62. Desmetz C, Bascoul-Mollevi C, Rochaix P, et al. Identification of a new panel of serum autoantibodies associated with the presence of in situ carcinoma of the breast in younger women. Clin Cancer Res. 2009; 15: 4733-41.
63. Fernandez-Madrid F, Tang N, Alansari H, et al. Autoantibodies to annexin XI-A and other autoantigens in the diagnosis of breast cancer. Cancer Res. 2004; 64: 5089-96.
64. Zhong L, Ge K, Zu JC, et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res. 2008; 3: doi:.
65. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol. 2007; 18: 868-73.
66. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001; 93: 1054-61.
67. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nature Med. 1995; 1: 701-2.
68. Finn OJ. Immune response as a biomarker for cancer detection and a lot more. N Engl J Med. 2005; 353: 1288-90.
69. Zhong L, Coe SP, Stromberg AJ, et al. Profiling tumour-associated antibodies for early detection of non-small cell lung cancer. J Thorac Oncol. 2006; 1: 513-9.
70. Chapman CJ, Murray A, McElveen JE, et al. Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. Thorax. 2008; 63: 228-33.